Archive

25 Jan 2017

Improved surveillance and diagnosis of rarer malaria parasites possible

The genomes of the two least common species of human malaria parasites are revealed today (25 January 2017) in Nature by a team of scientists from the Wellcome Trust Sanger Institute and their international collaborators. These sequences will enable improved surveillance and diagnosis of these rarer parasites that still cause more than 10 million malaria cases every year.

23 Jan 2017

This new mechanism found in 33 mutation hotspots in the genome.

Researchers at the Wellcome Trust Sanger Institute have discovered ‘hotspots’ of mutations in breast cancer genomes, where mutations thought to be inactive ‘passengers’ in the genome have now been shown to possibly drive further cancerous changes.

20 Jan 2017

Head of Cellular Genetics recognised with 20,000 Euros to further her research and an invitation to a research stay at Helmholtz Zentrum München (the German Research Centre for Environmental Health).

Dr Sarah Teichmann is one of five scientists to receive this year's Helmholtz International Fellow Award, and the only researcher from the medical sector to be honoured. The awards ceremony is scheduled for the 5 May 2017 at the Helmholtz Campus in Neuherberg near Munich.

16 Jan 2017

Acute myeloid leukaemia study finds personalised therapy is possible

An international collaboration led by clinical researchers at the Wellcome Trust Sanger Institute has shown proof-of-concept that truly personalised therapy will be possible in the future for people with cancer.  Details of how a knowledge bank could be used to find the best treatment option for people with acute myeloid leukaemia (AML) are published today (16 January 2017) in Nature Genetics

11 Jan 2017

Study reveals Spns2 gene as a new drug target

Research led by the Wellcome Trust Sanger Institute has discovered a new biological target for drugs to reduce the spread of tumours in cancer patients.  Published in Nature today (11 January 2017), the study with genetically modified mice found 23 genes that are involved in regulating the spread of cancers. The researchers showed that targeting one of these genes – Spns2 – led to a three-quarters reduction in tumour spread.

19 Dec 2016

International collaboration finds associations with four regions of the genome in PSC patients

Primary Sclerosing Cholangitis (PSC) is a rare disease of the liver with no effective treatment. Researchers identify four regions of the genome associated with the disease, one of which is a potential drug target.

19 Dec 2016

Based on ground-breaking research at the Wellcome Trust Sanger Institute into the role of the human microbiome in disease. Goal is to create the world’s leading company focused on microbiome biology and its use in medicine. Cambridge Innovation Capital and IP Group co-lead £8m funding round. 

Microbiotica has been established to commercialise ground-breaking research, conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute, into the role of the human microbiome in health and disease and its application to medicine. The HMIL is led by Dr Trevor Lawley and collaborates with the Professor Gordon Dougan research group.

30 Nov 2016

Researchers from the Wellcome Trust Sanger Institute and Imperial College London have developed Microreact, a free, real-time epidemic visualisation and tracking platform that has been used to monitor outbreaks of Ebola, Zika and antibiotic-resistant microbes

Microreact.org is a cloud-based system that combines the power of open data and the web, to provide real-time global data sharing and visualisation, allowing anyone to explore and examine outbreak information with unprecedented speed and detail. In collaboration with the Microbiology Society, any researcher around the world will be able to share their latest information about disease outbreaks.

29 Nov 2016

Two new methods will allow researchers world-wide to rapidly and accurately explore the changing role of genes as the cells develop into tissues such as liver, skin or heart, and discover how this contributes to health and disease.

Wellcome Trust Sanger Institute and University of Cambridge researchers have created sOPTiKO, a more efficient and controllable CRISPR genome editing platform. Today (29 November), in the journal Development, they describe how the freely available single-step system works in every cell in the body and at every stage of development. This new approach will aid researchers in developmental biology, tissue regeneration and cancer.

24 Nov 2016

Company founded on Institute technology goes from strength to strength.

Kymab is a company founded on genetic technologies developed at the Wellcome Trust Sanger Institute by Professor Allan Bradley. Its focus is discovering, developing and delivering new monoclonal antibody medicines to treat a variety of diseases.

Pages